The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy.
Renal cell carcinoma (RCC) remains a difficult management problem, because of the high metastatic rate and insensitivity of metastatic RCC to the traditional cytokine-based immunotherapy such as interleukin-2 and interferon-alpha. Regulatory T cells had a crucial role in impeding immune surveillance against cancer and hampering the development of effective anti-tumor immunity. At the same time cyclooxygenase-2 derived prostaglandin E2 played an important role in the transformation of regulatory T cells and could strengthen the inhibitory function of regulatory T cells. Previous experiment characterized that cyclooxygenase-2 was highly expressed in RCC. Herein, we draw the hypothesis that cyclooxygenase-2 inhibition may dampen the transformation of regulatory T cells and in turn contribute to eradicating RCC by the immune system. The clinical application of cyclooxygenase-2 inhibitors may strengthen the sensitivity of RCC to cytokine-based immunotherapy.
Li
Jinfeng
J
Fudan University, Department of Urology, No. 180 Fenglin Road, Zhongshan Hospital, Shanghai, China.
Wang
Guomin
G
Chu
Yiwei
Y
Rong
Ruiming
R
Zhu
Tongyu
T
D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000628:therapy*; D051546:Cyclooxygenase 2 / Q000187:drug effects* / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000628:therapy*; D008962:Models, Theoretical
D016861:Cyclooxygenase Inhibitors; D051546:Cyclooxygenase 2